Background Pneumococcal disease is a leading cause of morbidity and mortality worldwide. The aim of this study was to investigate the association between specific pneumococcal serotypes and mortality from invasive pneumococcal disease (IPD). Methods and Findings In a nationwide population-based cohort study of IPD in Denmark during 1977–2007, 30-d mortality associated with pneumococcal serotypes was examined by multivariate logistic regression analysis after controlling for potential confounders. A total of 18,858 IPD patients were included. Overall 30-d mortality was 18%, and 3% in children younger than age 5 y. Age, male sex, meningitis, high comorbidity level, alcoholism, and early decade of diagnosis were significantly associated with mortality. Among individuals aged 5 y and older, serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A were associated with highly increased mortality as compared with serotype 1 (all: adjusted odds ratio ≥3, p<0.001). In children younger than 5 y, associations between serotypes and mortality were different than in adults but statistical precision was limited because of low overall childhood-related mortality. Conclusions Specific pneumococcal serotypes strongly and independently affect IPD associated mortality.
References
[1]
[No authors listed] (2007) Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 82: 93–104.
[2]
Cherian T (2007) WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26–27 October 2006, Geneva. Vaccine 25: 6557–6564.
[3]
Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA (2007) Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369: 389–396.
[4]
Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196: 1346–1354.
[5]
Hanage WP (2007) Serotype replacement in invasive pneumococcal disease: where do we go from here? J Infect Dis 196: 1282–1284.
[6]
Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, et al. (2007) Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 468–472.
[7]
Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30: 100–121.
Mangtani P, Cutts F, Hall AJ (2003) Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 3: 71–78.
[10]
Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, et al. (2007) Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 45: 46–51.
[11]
Hjuler T, Wohlfahrt J, Staum KM, Koch A, Biggar RJ, et al. (2008) Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics 122: e26–e32.
[12]
Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, et al. (1998) An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 338: 1861–1868.
[13]
Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, et al. (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187: 1424–1432.
[14]
Sleeman KL, Griffiths D, Shackley F, Diggle L, Gupta S, et al. (2006) Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 194: 682–688.
[15]
Sandgren A, Sjostrom K, Olsson-Liljequist B, Christensson B, Samuelsson A, et al. (2004) Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 189: 785–796.
[16]
Ostergaard C, Brandt C, Konradsen HB, Samuelsson S (2004) Differences in survival, brain damage, and cerebrospinal fluid cytokine kinetics due to meningitis caused by 3 different Streptococcus pneumoniae serotypes: evaluation in humans and in 2 experimental models. J Infect Dis 190: 1212–1220.
[17]
Engelhard D, Pomeranz S, Gallily R, Strauss N, Tuomanen E (1997) Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 175: 979–982.
[18]
Tilghman RC, Finland M (1937) Clinical significance of bacteraemia in pneumococci pneumonia. Arch Intern Med 59: 602–619.
[19]
Austrian R, Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60: 759–776.
Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, et al. (2006) Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42: 451–459.
[22]
Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2006) Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 25: 602–607.
[23]
Mufson MA, Kruss DM, Wasil RE, Metzger WI (1974) Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med 134: 505–510.
[24]
Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, et al. (2006) Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 38: 427–432.
[25]
Rückinger S, von Kries R, Siedler A, van der Linden M (2009) Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatric Inf Dis J 28: 118–122.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53: 441–449.
[28]
Sorensen UB (1993) Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 31: 2097–2100.
[29]
Henrichsen J (1995) Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33: 2759–2762.
[30]
Pebody RG, Hellenbrand W, D'Ancona F, Ruutu P (2006) Pneumococcal disease surveillance in Europe. Euro Surveill 11: 171–178.
[31]
Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen J Jr., Hjuler T, et al. (2008) Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000–2005. Vaccine 26: 3765–3771.
[32]
H？gh B, Konradsen HB, Kristensen K, Hansen KG, Kofoed PE, et al. (2003) Pneumococcal vaccination of high-risk children [Pneumokokvaccination af risikob？rn]. Ugeskr L？ger 165: 4032.
[33]
Hammerum AM, Heuer OE, Emborg HD, Bagger-Skjot L, Jensen VF, et al. (2007) Danish integrated antimicrobial resistance monitoring and research program. Emerg Infect Dis 13: 1632–1639.
[34]
Kaltoft MS, Zeuthen N, Konradsen HB (2000) Epidemiology of invasive pneumococcal infections in children aged 0–6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl 893–10.
[35]
Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46: 263–268.
[36]
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
[37]
Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, et al. (2008) Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31: 1541–1545.
[38]
Walter SD (1978) Calculation of attributable risks from epidemiological data. Int J Epidemiol 7: 175–182.
[39]
Natarajan S, Lipsitz SR, Rimm E (2007) A simple method of determining confidence intervals for population attributable risk from complex surveys. Stat Med 26: 3229–3239.
[40]
Hsueh PR, Wu JJ, Hsiue TR (1996) Invasive Streptococcus pneumoniae infection associated with rapidly fatal outcome in Taiwan. J Formos Med Assoc 95: 364–371.
[41]
Henriques B, Kalin M, Ortqvist A, Olsson LB, Almela M, et al. (2000) Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 182: 833–839.
[42]
Rios AM, de la Hoz F, Leal AL, Castillo O, Castaneda E (1999) [The impact of antimicrobial resistance and Streptococcus pneumoniae serotype distribution on the mortality of children under 5 years of age with invasive disease]. Rev Panam Salud Publica 5: 69–76.
Pletz MW, Maus U, Krug N, Welte T, Lode H (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32: 199–206.
[45]
Spratt BG, Greenwood BM (2000) Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356: 1210–1211.
[46]
Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL (2006) Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 42: 907–914.
[47]
Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, et al. (2000) Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 132: 182–190.
[48]
Schonheyder HC, Sorensen HT, Kristensen B, Korsager B (1997) Reasons for increase in pneumococcal bacteraemia. Lancet 349: 1554.
